Cargando…
Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
Sorafenib, a multi-tyrosine kinase inhibitor, is a standard treatment for advanced hepatocellular carcinoma (HCC). The present study was undertaken to determine whether the growth and metastasis of HCC were influenced in mice receiving sorafenib prior to implantation with tumors, and to investigate...
Autores principales: | Zhang, Qiang-Bo, Sun, Hui-Chuan, Zhang, Ke-Zhi, Jia, Qing-An, Bu, Yang, Wang, Miao, Chai, Zong-Tao, Zhang, Quan-Bao, Wang, Wen-Quan, Kong, Ling-Qun, Zhu, Xiao-dong, Lu, Lu, Wu, Wei-Zhong, Wang, Lu, Tang, Zhao-You |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568028/ https://www.ncbi.nlm.nih.gov/pubmed/23409093 http://dx.doi.org/10.1371/journal.pone.0055945 |
Ejemplares similares
-
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016) -
Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma
por: Lu, Lu, et al.
Publicado: (2013) -
Arsenic trioxide induces differentiation of CD133(+) hepatocellular carcinoma cells and prolongs posthepatectomy survival by targeting GLI1 expression in a mouse model
por: Zhang, Ke-Zhi, et al.
Publicado: (2014) -
The Prometastatic Microenvironment of the Liver
por: Vidal-Vanaclocha, Fernando
Publicado: (2008) -
Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)